Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Monday,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock.

A number of other brokerages also recently issued reports on ORKA. TD Cowen began coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Lifesci Capital initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA opened at $18.51 on Monday. The company has a market cap of $647.85 million, a P/E ratio of -2.96 and a beta of 0.87. The company has a fifty day simple moving average of $26.02. Oruka Therapeutics has a 1 year low of $18.39 and a 1 year high of $53.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC bought a new position in Oruka Therapeutics in the 3rd quarter worth about $343,000. Wellington Management Group LLP bought a new position in Oruka Therapeutics in the 3rd quarter worth about $2,013,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the 3rd quarter worth about $1,037,000. Frazier Life Sciences Management L.P. bought a new position in Oruka Therapeutics in the 3rd quarter worth about $11,699,000. Finally, Janus Henderson Group PLC bought a new position in Oruka Therapeutics in the 3rd quarter worth about $5,840,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.